Clever Culture Systems (CC5) H2 2026 earnings summary

Executive summary

• Expanded global pharmaceutical customer base to 8, including major names like Novo Nordisk, Boehringer Ingelheim, CSL, and an unnamed top-20 company, doubling from prior year.

• Achieved 11 APAS Independence instrument placements, with over 30 instruments now installed globally and 22 deployed with pharmaceutical customers.

• Annual recurring revenue from software and service increased to $1.3 million, up from $0.7 million in 2025.

• APAS Independence recognized with industry awards and positive third-party validation from customers such as AstraZeneca, Bristol Myers Squibb, and Pfizer.

• Completed development and launch of the contact plate analysis module, providing a complete solution for environmental monitoring.

Financial highlights

• Revenue from customers was $4.3 million, down from $5.5 million in 2025, due to a higher proportion of evaluation and lease sales.

• Net loss after tax was $2.24 million, compared to a $1.68 million profit in 2025.

• Loss before income tax increased to $4.72 million from $0.09 million loss in 2025, mainly due to lower revenue, increased staff and development costs, and absence of prior year government grants.

• Cash balance at year-end was $1.7 million, with $3.4 million in expected inflows over the next two quarters.

• Net assets increased to $7.5 million, up from $5.6 million, largely due to recognition of deferred tax assets.

Outlook and guidance

• FY27 expected to deliver a step change in sales growth, with majority of sales anticipated from existing customers.

• Sales pipeline includes 180 qualified opportunities, with 8 existing pharma customers representing potential for 100 additional instrument sales.

• Focus remains on expanding within current accounts and executing on the Land and Expand strategy.